Pfizer abandons deal with Repligen on SMA drug candidate
US biologics specialist Repligen (Nasdaq: RGEN) revealed in a filing with the Securities and Exchange Commission that pharma giant Pfizer (NYSE: PFE) is terminating its 2012 agreement for the development of compounds to treat spinal muscular atrophy (SMA). The termination of the license agreement will become effective as of April 26, 2015.
Under the initial deal, Pfizer $5 million up front and committed to payments of a further $65 million in milestones to gain rights for RG3039, a Phase I drug designed to block enzyme DcpS and improve survival and motor function in SMA patients. Pfizer gave no reason for its decision.
Roche’s muscle forces out competitor, says EP Vantage
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze